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Abstract.  Hepatocyte Growth Factor (HGF, also 
known as Scatter Factor)  is a powerful mitogen or 
motility  factor in different cells,  acting through  the 
tyrosine kinase  receptor encoded by the MET proto- 
oncogene.  Endothelial  cells express the MET gene and 
expose at the cell surface the mature protein  (p190  MEt) 
made of a  50 kD (o0 subunit disulfide linked to a 
145-kD (~) subunit.  HGF binding to endothelial  ceils 
identifies two sites with different affinities.  The higher 
affinity binding  site (Kd  =  0.35 nM)  corresponds  to 
the p190  MET receptor.  Sub-nanomolar  concentrations  of 
HGF, but not of a recombinant  inactive precursor, 
stimulate the receptor kinase  activity, cell proliferation 
and motility.  HGF induces repairs  of a  wound in 
endothelial  cell monolayer.  HGF stimulates  the scatter 
of endothelial  cells grown on three-dimensional  col- 
lagen gels,  inducing  an elongated phenotype.  In the 
rabbit cornea,  highly purified  HGF promotes neo- 
vascularization  at sub-nanomolar  concentrations.  HGF 
lacks activities related to hemostasis-thrombosis, 
inflammation  and endothelial  cells accessory functions. 
These data show that  HGF is an in vivo potent angio- 
genic factor and  in vitro induces endothelial  cells to 
proliferate  and  migrate. 
H 
EPATOCYTE growth factor (HGF)' and scatter factor 
were originally identified as distinct cytokines that 
promote, respectively, the growth or motility of epi- 
thelial  cells.  HGF was identified in the serum of partially 
hepatectomized rats as a potent mitogen for cultured rat he- 
patocytes  (Nakamura  et al.,  1984;  Michalopoulos  et  al., 
1984). It has later been isolated from rat platelets (Nakamura 
et al., 1986), human plasma (Gohda et al., 1988), human se- 
rum  (Zarnegar  and  Michalopoulos,  1989),  and  rat  liver 
(Asami et al.,  1991). The HGF cDNA has been cloned and 
sequenced (Miyazawa et al.,  1989; Nakamura et al.,  1989; 
Tashiro et al.,  1990; Rubin et al.,  1991).  Scatter factor was 
originally described as a secretory product of fibroblasts that 
dissociates normal and malignant epithelial cells in vitro, in- 
creasing their motility and invasiveness (Stoker et al.,  1987; 
Gherardi et al.,  1989; Weidner et al.,  1990). Recently, se- 
quence  analysis  (Gherardi  and  Stoker,  1990)  and  cDNA 
cloning  from  fibroblasts,  placenta,  and  liver  showed that 
HGF and scatter factor are identical molecules (Weidner et 
al.,  1991; Naldini et al.,  1991a).  HGF is a disulfide-linked 
heterodimer of a 55-65 kD (~) and a 32-36 kD (/3) subunits 
(Nakamura et al.,  1987;  Godha et al.,  1988; Zarnegar and 
Michalopoulos, 1989; Gherardi et al., 1989; Weidner et al., 
1.  Abbreviations  used in  this paper:  GM-CSF,  granuloeyte-macrophage 
colony stimulating  factor; HGF, hepatocyte growth factor;  PAF, platelet- 
activating  factor;  PCA,  procoagulant  activity;  PCR,  polymerase  chain 
reaction. 
1990).  The  ~  and  3  subunits  originate  from  proteolytic 
cleavage of a single 92-kD inactive precursor (Miyazawa et 
al., 1989; Nakamura et al., 1989; Tashiro et al., 1990; Hart- 
mann  et  al.,  1992).  The  molecular  identity  of the  two 
cytokines has been further proven by their interchangeable 
activities in promoting hepatocyte growth, epithelial cell dis- 
sociation, and matrix invasion (Naldini et al.,  1991a; Weid- 
ner et al.,  1991;  Furlong et al.,  1991). 
Furthermore, HGF and scatter factor are indistinguishable 
ligands for the receptor encoded by the METproto-oncogene 
(pl90MEr), and both can stimulate the tyrosine kinase activ- 
ity of the receptor  (Naldini  et al.,  1991a,b).  The p190  MEt 
receptor is a  transmembrane  tyrosine kinase  (Park et al., 
1986) made of a 50 kD (or) subunit disulfide linked to a 145 
kD (3)  subunit  (Giordano  et al.,  1988,  1989a,b).  Ligand 
binding induces kinase activation (Bottaro et al.,  1991; Nal- 
dini et al., 1991b), receptor phosphorylation at specific tyro- 
sine sites (Ferracini et al.,  1991) and recruitment intracellu- 
lar signal transducers such as phosphatidyl inositol-3-kinase 
(Graziani et al.,  1991). 
The target cells responsive to HGF have not yet been fully 
identified.  The  cognate  receptor,  p190  MEt, has  been  de- 
tected so far in a variety of epithelial cells (Chan et al., 1988; 
Giordano et al.,  1989b; Naldini et al.,  1991b;  Di Renzo et 
al., 1991; Prat et al., 1991). HGF is expressed in several or- 
gans (Tashiro et al.,  1990; Zarnegar et al.,  1990) including 
vascular smooth muscle cells (Rosen et al.,  1990a).  HGF 
stimulates in vitro keratinocytes (Matsumoto et al.,  1991) 
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determines the spatial arrangement of epithelial cells (Mon- 
tesano et al.,  1991). Induction of"scattering" and thymidine 
incorporation in cultured endothelial cells has also been ob- 
served (Rosen et al.,  1990b; Rubin et al.,  1991; Morimoto 
et al.,  1991). 
Because of its distinctive ability to act as a  mitogen, a 
motogen and a morphogen, HGF is an ideal candidate to or- 
chestrate the biological processes leading to the development 
of normal  or pathological complex structures  (organs  or 
tumors).  In both cases the formation of new blood vessels 
is  required.  Here,  we  report  that  HGF  stimulates  the 
proliferation and the migration of endothelial cells in vitro 
and has angiogenic properties in vivo. 
Materials and Methods 
Purification of  Human and Murine HGF 
Human HGF was purified to homogeneity from tissue culture medium con- 
ditioned by the human fibroblast line MRC5,  grown on Cytodex beads 
(Pharmacia Fine Chemicals, Piscataway,  NJ) in a 3 liter bioreactor (Ap- 
plikon, Schiedam, Netherlands) equipped with automatic control of pH, 
CO2, and 02. The steps described by Weidner et al.(1990) were followed. 
Briefly, filtered medium (0.45-#m membrane; Millipore Continental Water 
Systems,  Bedford,  MA)  was  loaded onto a  heparin-Sepharose column 
(Pharmacia Fine Chemicals) at 4~  After washing with 0.5 M NaC1,  50 
mM Tris-HC1,  pH 7.5, HGF was eluted by a linear gradient (0.5-1.8  M) of 
NaC1,  with a  flow of 10 ml/h. Effluent aliquots were analyzed by SDS- 
PAGE, followed by silver staining. The biological activity was determined 
by the scatter assay described below. Further purification of  pooled fractions 
containing HGF activity (0.9-1.3  M  NaCI) was performed by cation ex- 
change chromatography on Bio-Rex 70 column (Bio-Rad Laboratories, 
Cambridge, MA) in 50 mM Tris-HC1,  pH 7.5. After dilution of the samples 
to reduce the salt concentration, scatter activity was eluted with a linear gra- 
dient of 0.2-1.2  NaCI  in  the  same buffer.  Biologically active  fractions 
(0.7-0.8  M  NaCI) were pooled. 
Murine HGF was purified to homogeneity from medium conditioned by 
ms transformed NIH-3T3 cells by a two-step procedure described in details 
elsewhere (Coffer et al., 1991). The factor was precipitated by ammonium 
sulphate at 60% saturation, dissolved in 50 mM MES, 0.1 M NaCI, pH 6, 
loaded onto a Mono S column (Pharmacia Fine Chemicals) and eluted by 
a linear gradient of NaCI (0.1-1.0 M). The pooled biologically active mate- 
rial was adsorbed onto an hydroxyapatite column (Bio-Rad Laboratories) 
equilibrated with 3 mM sodium phosphate buffer, pH 7.4, and eluted by a 
linear gradient of sodium phosphate (0.1-0.6  M). 
Purity of the final preparations was checked by SDS-PAGE etectrophore- 
sis after [125I] labeling as described below. Both the human and the murine 
HGF showed the expected three bands corresponding to the ~  chain (33 
kD), the a  chain (62 kD), and the uncleaved 92-kD precursor. The biologi- 
cal activity was monitored by the scatter assay on MDCK cells as described 
in details by Weidner et a1.(1990):  one unit was defined as the highest dilu- 
tion that clearly dissociates MDCK ceils and corresponded to 0.3 ng of pro- 
tein in a standard preparation. 
Molecular Cloning, Expression, and Site-directed 
Mutagenesis of  HGF cDNA 
The eDNA coding the 723 amino acid form of HGF was cloned as described 
in details elsewhere (Naldini et al., 1991a).  Briefly, amplification by poly- 
merase chain reaction (PCR) of liver HGF sequences was performed  on sin- 
gle stranded DNA templates obtained from human normal liver mRNA. 
For the amplification Vent polymerase (New England Biolabs, Beverly, 
MA), endowed with proof-reading activity,  was used. 30 PCR cycles were 
performed in a  Programmable Thermal Controller (MJ Research, Cam- 
bridge, MA) with a step cycle profile of 1 min at 92~  2 rain at 50~  and 
2 min at 72~  The PCR products were then purified and cloned in Blue- 
script plasmid vector (Stratagene, La Jolla, CA). DNA sequencing was per- 
formed on double-stranded DNA  using the deoxynucleotide procedure 
(Sanger, 1977).  Specific oligonucleotide primers were synthesized by stan- 
dard phosphoramidite methods with a  PCR-Mate 391  DNA Synthesizer 
(Applied Biosystem, Foster City, CA). The 2.2 kb BamHI-Sall HGF eDNA 
was inserted into the phagemid pSelect  TM vector and further processed to 
obtain the non cleavable (single chain) HGF mutant. The altered sites muta- 
genesis system (Promega Biotec, Madison, WI) was used to mutate a codon 
CGA (Arg) in CAA (Gin) within the sequence located between the nucleo- 
tide position 1467 and 1472.  The sequence Arg489-Va149~  in the HGF pri- 
mary translation product is recognized by a proteolytic processing system 
of the cell, leading to the dimer a-H. 
Wild type and the mutated constructs were cloned into the expression 
vectors pBAT (Frixen et al,, 1991) or pMT2 (Kaufman et al., 1989): pBAT 
(kindly  provided by  Dr.  W.  Birchmeier)  contains the promoter of the 
chicken ~  actin gene;  pMT2  the major  late adenovirus promoter.  The 
recombinant plasmids were obtained by ligation of a SacI-SalI HGF 2.2 kb 
fragment (for pBAT) and of a KpnI HGF fragment of the same size (for 
pMT2). The plasmids were transfected into Neuro2A (pBAT) or COS cells 
(pMT2) by the lipofection procedure. Three d after transfection superna- 
tants were collected and titrated in the scatter assay. 
Antibodies against the HGF Receptor 
Polyclonal rabbit antibodies were raised against a synthetic peptide corre- 
sponding  to  nineteen  COOH-terminal  amino  acids  (from  Set  1372  to 
Ser t39~ of the MET sequence (Ponzetto et al.,  1991; EMBL Data-Bank 
reference number X54559).  The peptide was coupled to keyhole limpet 
hemocyanin and the conjugate used to immunize rabbits. Antipeptide anti- 
bodies were purified on an affinity column of synthetic peptide coupled to 
CH-Sepharose 4B (Pharmacia Fine Chemicals). 
c-MET Probe and Northern Blot Analysis 
Total cellular RNA was prepared from monolayer cultures, using the single- 
step method of  extraction described by Chomczynski and Sacchi (1987). For 
Northern blot analysis RNA was fractionated by electrophoresis on 0.8% 
denaturing agarose gels and transferred to nitrocellulose. Hybridization was 
carried out at 42~  in the presence of 50%  formamide. The filters were 
washed at high stringency. The entire METcDNA was used as a probe. The 
full-size 4.3 kb HindIlI fragment was prepared from clones selected from 
a Xgtl 1 cDNA library obtained from the gastric carcinoma cell line GTL-16 
mRNA. 
Western Blotting and 7~rosine Phosphorylation 
Cells were directly solubilized in boiling Laemmli buffer (Laemmli, 1970), 
with or without reducing agents. Proteins, separated by SDS-PAGE, were 
transferred to nitrocellulose sheets and probed with anti-Met antibodies as 
described elsewhere (Giordano et al.,  1989a). The phosphorylation state 
of the HGF receptor was probed by anti-phosphotyrosine antibodies as de- 
scribed previously  (Comoglio et  al.,  1984).  Briefly,  subconfluent cell 
monolayers were made quiescent by 20 h starvation in serum-free Iscove's 
medium. After incubation with HGF for 10 rain at 37~  cells were lysed 
in a 25 mM Hepes buffer pH 7.6, containing 150 mM NaCl,  1%  NP-40, 
10% glycerol, 5 mM EDTA,  1 mM EGTA and protease and phosphatase 
inhibitors (50 t~g/ml pepstatin, 50/~g/ml leupeptin, 10 #g/ml aprotinin, 2 
mM PMSE 500 ttg/rnl soybean trypsin inhibitor,  100/~M ZnCI2,  1 mM 
Na orthovanadate). Proteins were immunoprecipitated by anti-Met antibod- 
ies, as described below,  separated by SDS-PAGE and analyzed in Western 
blots probed with anti-phosphotyrosine antibodies. Rabbit anti-mouse im- 
munoglobulin conjugated to  Horseradish-peroxidase and  the  Enhanced 
Chemiluminescence procedure (Amersham Corp., Arlington Heights, IL) 
were used. 
Cell Surface lodination and Immunoprecipitation 
Monolayers of cells were  incubated with  1  mCi  of [~25I] (Amersham 
Corp.),  and lactoperoxidase in the presence of exogenous H202  as de- 
scribed elsewhere (Naldini et al.,  1991a).  The reaction was arrested with 
cold PBS containing 0.02%  sodium azide. After labeling, cells were ex- 
tracted with ice cold buffer containing 10 mM Pipes, pH 7.6, 100 mM NaCI, 
5 mM MgC12, 300 mM sucrose, 5 mM EGTA,  1% Triton X-100, and in- 
hibitors of proteases as above. Cell extracts were precleaned on protein-A 
Sepharose and immunoprecipitated with rabbit antibodies. Immunocom- 
plexes  were  collected  on  protein-A  Sepharose,  washed  and  eluted  in 
Laemmli buffer with or without 2~-mercaptoethanol. 
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Pure murine HGF (1/zg) was radio-labeled with carrier free [125I] (2 mCi) 
(Amersham Corp.) and Iodogen (Pierce Chemical Co.). 200 #1 of Iodogen 
at 50 gg/ml in chloroform were dried in a polypropilene vial under nitrogen 
flow.  HGF and [t25I] were then added in phosphate buffer, pH 7.4.  The 
reaction was allowed to proceed for 15 min at 40C,  and then the mixture 
was transferred to another vial and left on ice for 10 rain. Carrier BSA was 
added to a final concentration of 0.1%  in 0.4 M  NaC1,  0.1% CHAPS, 20 
raM PO4 buffered to pH 7.4,  and the labeled ligand was fractionated from 
the free  [1251] by aff￿  chromatography on a  1 ml  heparin-Sepharose 
column (Pierce Chemical Co.) pre-equilibrated with the same buffer. After 
extensive washing, the column was eluted with  1.3 M  NaCI in the same 
buffer and  0.5-ml  fractions  were  collected.  Fractions  containing TCA- 
precipitable radioactivity were pooled, concentrated with a Centrisart (Sar- 
torius Balances, Westhury, NY) diafiltration apparatus with a membrane 
cut off above 20 kD and stored at 4~  The specific activity of the tracer 
was approximately 0.25 Ci/mg, corresponding to an I/HGF molar ratio of 
approximately 11/1. The radiolabeled factor retained its biological activity 
as scatter factor assayed on MDCK cell line. 
For binding displacement studies, cell monolayers were seeded at low 
density on collagen-coated microwells, put on ice, rinsed four times with 
prechilled RPMI medium containing 20 mM Hepes, pH 7.4, 0.1% BSA, 100 
/zg/ml soybean trypsin inhibitor and bacitracin (binding medium), and in- 
cubated with 0.05 nM [12sI]-HGF in binding medium, without or with the 
indicated concentrations of unlabelled competitor, for 3 h at 4~  in a final 
volume of 200 gl/well. The monolayers were then washed five times with 
the binding medium and extracted with 2% SDS in PBS. The extracts were 
then counted in a Packard -/-counter. Total binding was below 10% of the 
added cpm and specific binding-calculated subtracting from the total the 
cpm  bound  after  incubation  with  a  hundredfold  excess  of  unlabeled 
ligand-was "~75%.  Specific ligand binding studies were performed by 
using increasing concentrations of [1251]HGF in the presence of 50-fold ex- 
cess of cold ligand at 4~  for 3 h in the same conditions described above. 
The Kd of affinity binding sites was estimated by Lineweaver-Burk plot. 
Cell Growth  Assay 
2.5  x  103  human endothelial cells were plated in 96-well plates (code 
3595;  Costar, Cambridge, MA) coated with gelatin (Difco Laboratories, 
Detroit, MI; 0.05 %, for 1 h at 22~  in M199 medium containing 20% FCS 
(Irvine, Santa Ana, CA). After 24 h the medium was removed and replaced 
with M199 containing 5% FCS with or without factors. 1.2  x  103 and 1.8 
￿  103 tend.1 and eEnd.1 cells, respectively, were plated in DME contain- 
ing 10%  FCS. After 24 h the experiments were done in Iscove's medium 
(ICN Biomedical, Irvine, CA) supplemented with 6 mg/1 transferrin, 5 mg/l 
insulin, 100 nag soybean lecithin, 6.73 gg/1 sodium selenite, and 400 rag/1 
BSA.  Endothelial cells number was estimated after staining with crystal 
violet by a colorimetric assay described by Kueng et al. (1989).  Briefly, the 
cells were fixed for 20 rain at room temperature with 2.5 % glutaraldehyde 
and then stained with 0.1%  crystal violet in 20%  methanol. The stained 
cells were solubilized with acetic acid (10%); the wells were read at 595 
nm in a Microplate Reader (model 3550; Bio-Rad). A calibration curve was 
set up with known number of cells. Proportionality between absorbance 
and cell counts exists up to 8  x  10  a cells. 
Chemotaxis Assay 
Chemotaxis assays on human endothelial cells were performed as previ- 
ously described (Dejana et al., 1985; Bussolino et al., 1989) with the Boy- 
den chamber technique. Polycarbonate filters (5-#m pore size, polyvinyl- 
pyrrolidone-free; Nucleopore Corp., Pleasanton, CA) were coated with 
gelatin (Difco Laboratories; 0.1% for 6 h at room temperature). HGF in 
M199 containing  1%  FCS were seeded in the lower compartment of the 
chamber, and 2  ￿  103 suspended cells in M199 containing 1% FCS were 
then seeded in the upper compartments. After 8 h of incubation at 37~ 
the upper surface of the filter was scraped with a rubber policeman. The 
filters were fixed and stained with Diff-Quick (Harleco, Gibbstown, NJ), 
and  10 oil immersion fields were counted after coding samples. 
The  directedness of HGF-stimulated  migration  was  evaluated  using 
checkerboard analysis (Zigmond et al., 1973).  Increasing concentrations of 
HGF were placed in both top and bottom wells of the Boyden chamber in 
order to establish positive, absent, and negative concentration gradients 
across the filter barrier. Directed locomotion, chemotaxis, is the response 
to a net gradient of attractant; random stimulated migration, chemokinesis, 
is the response to attractant when no concentration gradient is present. 
Culture of  Human Endothelial Cells on 
Three-dimensional Collagen Gels 
Collagen gels were prepared as described by Montesano et al.  (1986). 
Briefly,  a solution of rat collagen type I (2 mg/mi in 0.1% acetic acid) was 
dialyzed for 40 h at 4~  against 4 liters of DME.  One ml of 10￿  DME 
and 2 ml of NaHCO3 (0.37 M) were added to 7 ml of the cold collagen so- 
lution in an ice bath: 0.4 ml of this mixture were then dispensed into 24-well 
plates and allowed to gelify for 20 rain at room temperature. 7  ￿  104 hu- 
man endothelial cells were plated onto the gel layer and let to grow to 
confluence in M199 medium containing 20% FCS. The scattering assay was 
performed by adding HGF to the monolayer at the indicated concentrations. 
The cultures were fixed in isotonic formaldehyde (3 %) for 30 min at room 
temperature and then observed under a Zeiss Axiophot microscope (Carl 
Zeiss, Oberkochen, Germany). 
Wound Assay 
Human endothelial cells were grown at confluence on 24-well plates (Falcon 
Plastics, Cockeysville, MD) coated with rat collagen (10 gg/ml). Mono- 
layers were wounded with a  razor blade as described (Bussolino et al., 
1991a). After wounding, the cells were washed with PBS and incubated in 
M199 medium (ICN Biomedical) containing 5 % FCS with or without HGE 
Endothelial cells were fixed and stained with crystal violet as described 
above. 
Procoagulant Activity, PAF Synthesis, and ELAM-I, 
VCAM-1, and Class H MHC Antigen Expression 
Platelet activating factor (PAF) extracted from human endothelial cells was 
purified by TLC-HPLC,  characterized, and quantified by aggregation of 
washed rabbit platelets as described (Bussolino et al., 1988).  Procoagulant 
activity (PCA) was measured in a one-stage clotting assay on human en- 
dothelial cells monolayers grown on gelatin coated wells,  according to 
Bevilacqua et al.  (1984).  103 mU of standard PCA scored a clotting time 
of 23  s.  The  expression of endothelial-leukocyte adhesion molecule-1 
(ELAM-1), vascular cell adhesion molecule-1 (VCAM-1), and class II MHC 
antigens (HLA-Dr)  was measured by immunofluorescence after staining 
with specific mAbs. The cells were stimulated with HGF for 4 h before the 
PCA assay, 6 h before measuring PAF synthesis or ELAM-I expression, 12 
h  before VCAM-1  and 96  h  before HLA-Dr determination.  These time 
points have been selected from preliminary time-course experiments lasting 
from 5 min to 96 h. IL-1B and TNF-~ were used as positive controls for 
the production of PAE PCA, and the expression of ELAM-1 and VCAM-1, 
both at 10 ng/ml, which is optimal concentration for these activities (Bus- 
solino et al., 1988; Bevilacqua et al., 1984,  1989).  The positive control for 
the expression of HLA-Dr antigens was INF-% used at 500 mg/mi (Pober 
et al.,  1986). 
In Vivo  Angiogenic Assay 
The angiogenic activity of HGF was assayed in vivo using the rabbit cornea 
assay described in details previously by some of us (Ziche et al., 1989; Bus- 
solino et al.,  1991a).  Slow-releasing pellets (1  ￿  1 ￿  0.5 ram) were pre- 
pared in sterile conditions incorporating the dried HGF into a casting solu- 
tion of a vinyl copolymer (Elvax 40;  Dupont, Wilmington, DE), in 10% 
methylene chloride (10/A/droplet). In the lower half of New Zealand white 
rabbit  eyes  (Charles  River  Breeding  Laboratories,  Wilmington,  DE), 
anesthetized by pentobarbital (30 mg/Kg), a microsurgical pocket (1.5 ￿  3 
mm), was produced using a pliable iris spatula 1.5-mm wide. The pellets 
were implanted in the micropockets, located into the transparent avascular 
corneal stroma. Subsequent daily observations of the implants were made 
with a  slit lamp stereomicroscope without anesthesia. An angiogenic re- 
sponse was scored positive when budding of vessels from the limbal plexus 
occurred before 3-4 d and capillaries progressed to reach the implanted pel- 
let according to the scheme previously reported (Bussolino et al.,  1991a). 
Angiogenic activity was expressed as the number of implants exhibiting 
neovascularization over the total implants studied. Potency was scored by 
the number of newly formed vessels and by their growth rate. 
Cells 
Human endothelial cells from umbilical cord vein, prepared and character- 
ized as previously described (Bussolino et al., 1989),  were grown in M199 
medium supplemented with 20% FCS (Irvine), endothelial cell growth fac- 
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(I-IV). The mouse endothelioma cell lines eEnd.1, and tEnd.1 were ob- 
tained through the courtesy of Dr. E. E Wagner (IMP, Wien; Williams et 
al., 1989). These cell lines, originally derived from a thymic (tEnd.I) and 
embryonal (eEnd.1) hemangioma, express the polyoma middle T antigen, 
and  have morphological and  functional features of microvascular en- 
dothelial cells (Bussolino  et al., 1991b). The lines were maintained in DME 
(Gibco Laboratories, Grand Island, NY) containing 15 % FCS and 750 mg/l 
G418 (Gibco Laboratories). The human diploid fibroblast MRC5 line was 
from American Type Culture Collection (Rockville, MD), and was grown 
in DME supplemented  with 10% FCS.  The human vascular smooth muscle 
ceils were kindly provided  by Dr. M. Trovati  (University  of Torino, Torino, 
Italy) and grown in DME supplemented with 20%  FCS. The EA926 en- 
dothelial cell line (kindly provided by Dr. E. C. J. Edgell, University of 
North Carolina at Chapel Hill, Chapel Hill) was maintained in DME sup- 
plemented with 10% FCS. 
Reagents 
TNFc~ (1  x  106 U/mg protein) was obtained from Dr. E  Ralph (Cetus 
Corp., Berkeley,  CA); basic-fibroblast  growth factor (bFGF) from Farmita- 
lia; human IFN), (1  x  106 U/rag protein) from Biogen (Geneva, Switzer- 
land);  human IL-1/~ (1  x  10  a U/mg protein) and human granulocyte- 
macrophage colony stimulating factor (GM-CSF) (1  x  107 U/mg) from 
Dr. Gillis (Immunex, Seattle, WA). 
Phosphotyrosine antibodies were raised against  p-amino-benzene-phos- 
phonate and affinity-purified as previously described (Comoglio et al., 
1984). mAbs anti-ELAM-1  and VCAM-I  were from British Bio-technology 
Limited; mAb antibody anti-class II-Dr antigens (AA3.84) were a gift of 
Dr. E Malavasi (University of Torino, Torino, Italy). S. Aureus  Protein A 
covalently coupled to sepharose was purchased from Pharmacia. Reagents 
for SDS-PAGE  and nitrocellulose filters were from Bio-Rad. All other re- 
agents were analytical grade from Sigma Chemical Co. 
Results 
Endothelial Cells Express the HGF Receptor 
Total  RNA  was  extracted  from  endothelial cells cultured 
from  human  umbilical cord  veins.  Northern  analysis was 
performed using the full-size METcDNA as a probe. A ma- 
jor transcript of 9  kb  was  observed (Fig.  1 A).  To  detect 
the protein, cell lysates were blotted and probed with poly- 
clonal rabbit antibodies directed against a  COOH-terminal 
peptide of the p190  MET 13 chain (Fig. 1 B). Proteins were ex- 
tracted from human endothelial cells prepared from the um- 
bilical cord  vein  and  from  a  human  endothelial  cell  line 
(EA926). In both cell lysates, analyzed under non-reducing 
conditions, a  single protein band of the expected size (190 
kD),  corresponding to the  o~/3 dimer,  was  detected.  After 
reduction of disulfide bonds, the fl chain alone (145 kD) was 
observed.  In these conditions a  170-kD band was also de- 
tected, corresponding to the prl70 receptor precursor previ- 
ously described (Giordano et al.,  1989b).  To visualize the 
mature  ct  subunit  exposed  at  the  cell  surface  with  the 
subunit,  the  cells were  labeled with  [~25I]-lactoperoxidase 
detergent extracted and  immunoprecipitated with the anti- 
Met antibody (Fig.  1  C).  Human  vascular smooth muscle 
cells, as well as a number of other cells of mesenchymal ori- 
gin,  were negative. 
HGF Binds and Stimulates the Receptor Kinase in 
Endothelial Cells 
Monolayers of human endothelial cells were incubated with 
0.05 nM of [tESI]-HGF in the presence of increasing concen- 
trations of unlabeled ligand. The ligand displacement curves 
at equilibrium showed specific binding of HGF to the cell 
surface and identified two classes of binding sites with differ- 
ing affinities. A  higher affinity HGF binding  site was  ob- 
served with a lower affinity, high capacity binding site (Fig. 
2 A). The higher affinity binding site was further character- 
ized  by  direct  binding  with  increasing  concentration  of 
[t25I]HGF  and  the  calculated  K~  was  0.35  nM  with  1@ 
receptors per cell (bmax  =  2.59  fmoles/cell) (Fig. 2  B). 
The  high  affinity HGF  receptor is the  p190  ~ET  tyrosine 
kinase (Naldini et al.,  1991a).  To  show that in human  en- 
dothelial cells the kinase activity is controlled by binding to 
the  specific  ligand,  studies  were  carried  on  using  phos- 
photyrosine antibodies. The receptor was solubilized from 
cells made quiescent by serum starvation and stimulated by 
Figure 1.  Expression of HGF 
receptor in human endothelial 
cells. (A) Northern blot anal- 
ysis  of total  RNA  extracted 
from control vascular smooth 
muscle cells (lane 1) and en- 
dothelial cells prepared from 
umbilical cord vein (lane 2). 
The eDNA probe encompass- 
ing the entire MET coding se- 
quence,  labeled  with  [32p], 
was  hybridized to  20  #g  of 
RNA.  X-ray  films  were  ex- 
posed for 14 d with intensify- 
ing screens. (B) Western blot 
analysis of total protein solu- 
bilized from endothelial cells 
prepared from umbilical cord 
vein (lanes 2  and 5),  EA926 
endothelial cell line (lanes 1 
and 3), or vascular smooth muscle cells (lane 4). Proteins (200 #g per well) were run under non-reducing (lanes 1-2) or reducing conditions 
(lanes 3-5) and probed with anti-Met antibodies directed against the 145-kD  fl chain.  (C) Immunoprecipitation of membrane proteins 
from endothelial cells, labeled with [1251] under non-permeating conditions. Proteins extracted by non-ionic detergent were precipitated 
by anti-Met antibodies and separated under non-reducing (lane 1 ) and reducing conditions (lane 2). 
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Figure 2.  Binding  of radiola- 
beled  murine HGF to human 
endothelial cells. (Top) Ligand 
displacement  curve.  Mono- 
layers  were  incubated  with 
0.05  nM  [~5I]-HGF  in  the 
presence of the indicated con- 
centrations  of unlabeled  HGF 
to equilibrium  binding at 4~ 
The points  are means  +  SD 
of  triplicate  determinations 
from a representative  experi- 
ment. (Bottom)  Specific ligand 
binding  curve.  Monolayers 
were incubated with indicated 
concentrations  of [I~5I]-HGF 
in the presence of 50-fold ex- 
cess of cold HGF.  The insert 
shows the analysis of the data 
by Linewear-Burk plot. 
HGE  After  immunoprecipitation  and  electrophoresis,  the 
receptor was blotted onto nitrocellulose  filters and probed 
with anti-phosphotyrosine antibodies.  The kinase activation 
was assessed by measuring the tyrosine auto-phosphoryla- 
tion of the/~  subunit.  Specific phosphorylation of p190  "ET 
was  observed  after  stimulation  with  natural  human  HGF 
purified from MRC5 cell supernatants or with recombinant 
HGF expressed in Neuro-2A cells (Fig. 3).  The specificity 
of the reaction was tested by using a recombinant HGF mole- 
cule with an inappropriate conformation.  The HGF cDNA 
expressed in Neuro-2A cells was mutated to convert Arg 4s9 
into a Gin. As described in details elsewhere (Hartmann et 
Bussolino et al. HGF Is an Angiogenic  Factor  633 Figure 3.  Tyrosine phosphor- 
ylation  of the HGF receptor in 
human  endothelial cells. Mono- 
layers prepared from umbili- 
cal cord  vein were incubated 
for 10 min at 37~  in serum- 
free  culture medium supple- 
mented as follows.  (Lane 1) 
Spent medium conditioned by 
Neuro-2A  cells  transfected 
with the vector alone. (Lane 2) 
Spent medium conditioned by 
Neuro-2A cells expressing the 
GIn4gg-HGF  mutant. (Lane 3) 
Supernatant  of Neuro-2A cells 
expressing the wild type HGF 
(12 ng/ml). (Lane 4) Purified human HGF (30 ng/ml). Proteins ex- 
tracted by non-ionic  detergent were immunoprecipitated by anti-Met 
antibodies, separated under reducing conditions,  blotted onto nitro- 
cellulose,  and probed  with antiphosphotyrosine antibodies. 
al., 1992), this point mutation eliminates the specific proteo- 
lytic site in the HGF precursor, leading to the secretion of 
an  uncleaved  inactive  molecule.  The  Arg489-HGF mutant 
was almost completely inactive in the phosphorylation assay 
(Fig.  3). 
HGF Stimulates the Growth of  Endothelial Cells 
In Vitro 
The mitogenic activity of HGF was studied using cultures of 
human endothelial cells  and two murine cell  lines derived 
from  embryonal  (eEnd.1)  or  microvascular  (tEnd.l)  en- 
dothelium.  Human endothelial cells,  seeded  at 2.5  x  l03 
per 0.32-cm  2 well,  undergo a  16-fold increase in cell num- 
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Figure 4.  Proliferation of human endothelial cells  stimulated by 
HGF: time-course (A) and dose dependence (B). Low density cul- 
tures of endothelial cells (2.5  x  103 per 0.32-cm 2 well) were incu- 
bated in M199 supplemented with 5% FCS in the presence (o) or 
in the absence (A) of human HGE Fresh factor was added every 
two days. B, cells were counted after 8 d. The data shown are the 
means of six determinations +  SD in a representative experiment. 
ber  over  an  8  d period when stimulated every  2  d  with 5 
ng/ml of natural human HGF (Fig.  4  A).  Challenging en- 
dothelial cells cultures with a unique pulse of the factor (5 
ng/ml) doubled the cell number within 6 d (not shown). The 
stimulatory  activity  was  concentration dependent,  with  a 
maximum effect occurring between 2.5 and 5 ng/ml. Higher 
concentrations were uneffective (Fig. 4 B). The same growth 
stimulatory activity was measured when human recombinant 
HGF was tested. Both the natural and the recombinant fac- 
tors  were  inactive  after  heat denaturation.  The  uncleaved 
Gin  4s9 mutant was as well nearly devoid of biological activ- 
Heated 
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alone 
rHcF 
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medium ~~--4 
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Number  of  cells  (x  1000) 
Figure 5.  Effect of natural or 
recombinant  HGF on the pro- 
liferation  of human endothe- 
lial cells.  Cell  proliferation, 
assayed in the conditions de- 
scribed in  the legend to Fig. 4, 
was measured 8 d after the ad- 
dition of the following factors: 
None,  fresh  medium;  HGF, 
purified human HGF; Heated 
HGF, the same reagent boiled 
for 3 min; Vector alone, spent 
medium conditioned by Neuro- 
2A  ceils  transfected  by  the 
empty  vector;  rHGF,  spent 
medium conditioned by Neuro- 
2A cells expressing  recombi- 
nant HGF; Gin 4s9 HGF, spent 
medium conditioned by Neuro- 
2A  cells  expressing  the  un- 
cleaved mutant HGF; MRC5 
medium, spent medium  condi- 
tioned by MRC5 cells.  Spent 
media were diluted to contain 
~5 ng/ml of HGE  The data 
shown are the means of six de- 
terminations 5: SD in a repre- 
sentative experiment. 
The Journal of Cell Biology, Volume 119, 1992  634 ity (Fig. 5). The conditioned medium harvested from the hu- 
man diploid fibroblast line MRC5, which is known to pro- 
duce active HGF (Gherardi et al.,  1989), seems to be more 
potent  in  stimulating  endothelial  cells  growth  than  the 
purified human HGF, either natural or recombinant (Fig. 5). 
This higher effect on growth was observed when identical 
"scatter"  units  of factor  were  tested  (see  Materials  and 
Methods), suggesting a possible cooperation with other fac- 
tor(s) present in the conditioned medium. 
We then compared the  growth  stimulatory activity of 
HGF with that induced by known angiogenic factors used 
at optimal concentration, namely GM-CSF (10 ng/ml) and 
basic-FGF (5 ng/ml). In the same experimental conditions 
HGF (5 ng/ml) (HGF: 4.0  +  0.3  x  1@ cells; control:  1.3 
+  0.2  x  104 cells) was approximately twofold more active 
than GM-CSF (2.3  +  0.2  x  104 cells), while less potent 
than bFGF (7.4  5:0.3  x  104). 
The growth stimulatory effect of HGF is not restricted to 
endothelial cells of human origin. Murine HGF stimulate the 
growth of  two murine endothelial cell lines originated by thy- 
mic (tEnd.l) and embryonic (eEnd.1) tissues (Williams et al., 
1989).  The stimulatory effect of HGF is detectable at 0.6 
ng/ml, and the optimal concentration is 2.5 ng/ml, which in- 
creases of about twofold the growth rate (tEnd.l" control, 3.1 
:t:  0.2  x  1@ cells;  HGF, 5.8  :k  0.3  x  10  4 cells,  eEnd.l: 
control,  2.2  +  0.1  x  104 cells;  HGF,  3.2  5:0.1  x  104 
cells).  No  stimulation  was  observed at higher concentra- 
tions.  The factor is partially species-specific since human 
HGF is twice as potent on human endothelial cells than on 
mouse cell lines. The same kind of species-specificity was 
observed for the murine HGF tested on mouse and human 
endothelial cells (Table I). 
HGF Enhances Endothelial Cell Motility 
The effect of HGF on endothelial cell motility was evaluated 
in  Boyden chamber.  The motility response was  exhibited 
with stimulated migration peaking at HGF concentration of 
2.5  ng/ml (Fig.  6).  At this concentration, the response to 
HGF  is  similar  to  that  elicited  by  fibrinogen  (1  mg/ml 
fibrinogen:  148  +  18  migrated  cells;  control  66  +  9 
Table I. Effect of Human and Murine HGF on 
Endothelial Cells* 
HUVEC  eEnd. 1  tEnd. 1 
1.  Control  8.2  +  0.3  17.3  +  1.1  19.0  +  2.1 
2.  human  HGF  22.2  +  1.2  24.5  +  2.3  23.1  +  0.8 
3.  murine  HGF  14.2  +  2.0  38.2  +  1.6  37.3  +  3.1 
* Number of cells (1  x  103). 
2.5  x  103 human umbilical cord vein endothelial cells (HUVEC) were seeded 
in 96-well microtiter plates (0.32 cm  ~) in 0.2 ml of M199 medium, containing 
5% FCS.  1.8  x  103 murine endothelial cells (eEnd. l) and 1..2 x  109 (tEnd. l) 
were seeded in 0.2 ml of Iscove's medium without serum modified as detailed 
in Materials and Methods. The cultures were stimulated with different HGFs 
as  indicated; fresh  factor was added every two days.  The cell number was 
scored at the plateau (8th day for human cells or 6th day for murine cells). 
Numbers are the mean (2: SD) calculated from six duplicates of one represen- 
tative experiment. For each data column, p was calculated by ANOVA and was 
always <0.0001.  Then Student-Neuwam-Keuls test was applied for more spe- 
cific comparisons.  The  following comparisons  gave p  <  0.05:  human  en- 
dothelial cells: 1 versus 2,  1 versus 3, 2 versus 3; eEnd.l: 1 versus 2,  1 versus 
3,  2  versus 3; tEnd. l:  1 versus 2,  1 versus 3,  2  versus 3. 
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Figure 6.  Migration of human endothelial cells stimulated with 
HGF. The migration of cells was measured by the modified Boyden 
chamber technique, as described in Materials and Methods. HGF 
in M199 containing 1% FCS were seeded in the lower compartment 
of the chamber, and 2 ￿  105 endothelial cells in the same medium 
were seeded in the upper compartment. Cells migrated after 8 h in- 
cubation to the lower surface of the filter were counted after coding 
samples. The numbers are the mean +  SD of three fields counted, 
in a representative experiment. 
migrated  cells)  used  as  positive  control  (Dejana  et  al., 
1985).  Heating  HGF  removed  the  migration-stimulating 
activity  (not  shown).  Checkerboard  analysis  shows  that 
HGF induced not only chemokinesis, but also chemotaxis 
(Table II). 
HGF Promotes Wound Repair in Endothelial 
Cell Monolayers 
Wound healing  assays  in  vitro,  i.e.,  the  ability  of filling 
artificial gaps created in cell monolayers, requires both cell 
growth and activation of cell movements. HGF induced re- 
pair,  in a  dose-dependent manner,  of mechanical wounds 
generated in human endothelial cells monolayers (Fig.  7). 
After 24 h of stimulation, endothelial cells moved into the 
denuded area, and completely filled the free space available. 
Movement was induced by as little as 5 ng/ml; the maximum 
effect was reached at concentrations around 50 ng/ml. When 
endothelial  cells  were  treated  for  60  min  at  37~  with 
mitomycin C (10 t~g/ml) and then stimulated with HGE the 
repair process observed after 24 h was significantly reduced. 
This shows that the process requires both cell migration and 
DNA synthesis (data not shown). The heat-inactivated and 
the Gin  489 mutant HGF were inactive (data not shown). 
Bussolino et al.  HGF Is an Angiogenic Factor  635 Table II. Checkerboard Analysis of  Induction of  Endothelial 
Cell Migration by HGF 
Upper chamber 
HGF  HGF  HGF 
Lower chamber  Medium  1 ng/ml  2.5  ng/ml  5 ng/ml 
Medium  61  +  7  58  +  7  51  +  3  49  +  10 
HGF  1 ng/ml  80  +  4*  67  +  2  74  _  3*  65  +  3 
HGF 2.5  ng/ml  92  5:  3*  81  5:  2*  83  5:  4*  71  5:  5* 
HGF 5  ng/ml  129  5:  3*  117  +  4*  100  5:  6*  77  5:  3* 
Different concentrations  of purified  natural  HGF were  placed  in the  upper 
and/or lower compartments of the Boyden chamber.  Results are expressed as 
the number of migrated cells (mean  _+  SD of three  samples for each experi- 
mental point). 
* P <  0.05  versus medium control,  by t-test. 
HGF Stimulates Endothelial Cell Scattering on 
Collagen Three-dimensional Gel 
Endothelial cells plated onto plastic surface do not constitute 
colonies as epithelial cells. This characteristic does not per- 
mit study of the scatter activity of HGF as dispersion of cell 
colonies.  To investigate whether  HGF can  induce  scatter, 
human endothelial  cells were plated on three-dimensional 
collagen gels. After the attainment of confluence the mono- 
layers were stimulated with sub-nanomolar concentrations of 
the factor. Scatter along this three-dimensional structure was 
examined by observing scattered cells whose plane of focus 
was obviously within or beneath the layer of the collagen gel 
(Fig.  8).  The treated cells  monolayer started to penetrate 
through the matrix within 24 h.  After 4  d of culture in the 
presence of HGE the matrix was filled by endothelial cells 
showing  the  characteristic  elongated  phenotype  sprouting 
cytoplasmic extensions and ruffles (Fig. 8 d). HGF also in- 
duced a network of branched and associated elongated cells, 
often anastomosed with one another (Fig.  8, e and f).  En- 
dothelial cells maintained in control medium during the same 
time  retained  their  characteristic  cobblestone  appearance 
and did not scatter along the underlying matrix (Fig.  8, a 
and b). 
HGF Does Not Affect Activities Related to 
Thrombosis, Inflammation, and Other Endothelial 
Cells Functions 
The ability of HGF to modulate endothelial cell functions 
related to thrombosis, inflammation and the so called acces- 
sory functions was investigated by measuring the following 
parameters:  (a)  induction  of procoagulant activity  (PCA) 
and of platelet activating factor (PAF); (b) modulation of ex- 
pression  of  cell  adhesion  molecules  (e.g.,  ELAM-1  and 
VCAM-1);  and  (c)  expression  of HLA-Dr antigens.  Inter- 
leukin-l~, Tumor Necrosis Factor c~, IFN3,, were used as ref- 
erence standards.  HGF did not affect with any one of the 
listed activities (Table III). 
In Vivo Angiogenic Effect of  HGF 
To explore the real relevance of HGF to the angiogenesis in 
vivo, we studied the formation of new capillary vessels in the 
rabbit cornea.  Purified HGF was incorporated into a vinyl 
copolymer pellet and implanted in a corneal pocket 2  mm 
from the limbus. The factor is released in the avascular trans- 
Figure 7. Wound healing of human endothelial cells monolayer in- 
duced by HGF. Confluent stationary  endothelial  cell monolayers 
were wounded with two cross-shaped scratches of different width. 
After a 24-h recovery, monolayers were incubated in the absence 
(top) or in the presence of HGF 5 ng/ml (middle) or 12 ng/ml (bot- 
tom), corresponding to the indicated Scatter Units (U). The thinner 
scratch was filled completely at both concentrations. 
The Journal of Cell Biology, Volume  119, 1992  636 Figure 8. Scattering within three-dimensional  collagen gel by human endothelial cells stimulated with HGF. (Phase contrast microscopy 
in a, c, and e; Nomarsky interference microscopy in b, d, and f). Untreated cells formed cobblestone-like  monolayer at the surface of 
collagen gels after 4 d of culture.  Cells treated with HGF (5 ng/ml) for 4 d scattered acquiring a dendritic or irregular  shape (the plane 
of focus is beneath that of the monolayer).  In some instances cells formed an incomplete network of branching cell cords.  Bars: (a and 
b) 20/xm; (c and d) 30 #m; (e and f) 17 ttm. 
parent cornea around  the pellet and generates a  gradient. 
The neo-formation of capillaries from the limbus was moni- 
tored  (Fig.  9),  HGF  promoted  capillary  outgrowth  in  a 
significant number of animals (p <  0.05).  The angiogenic 
effect was dose-dependent and seen within a sub-nanomolar 
range of concentrations (Table IV). The newly formed vessel 
network consisted approximately of 30-40 capillaries that 
reached and surrounded the pellet implant by d  8. No signs 
Bussolino et al. HGF Is an Angiogenic Factor  637 Table IlL Stimulation of  PAF Synthesis, Procoagulant Activity, ELAM-1,  VCAM-1, and Class II MHC Antigen 
Expression in Human Endothelial Cells 
% positive cells 
Growth*  PAF pmoles  PCA mU  ELAM-I  VCAM-I  HLA-Dr 
Control  3.3  +  1.1  0.4  +  0.2  6  +  4  0  0-2  0 
HGF  29.2  +  0.4  0.5  +  0.2  11  +  5  0-4  0-2  0 
IL-I/3  12.2  _  1.3  1.2  +  0.1  116  +  7  43-67  25-52  0-3 
TNFc~  14.3  +  2.0  2.9  +  0.7  167  +  18  50-61  40-55  0 
INF7  9.8  +  1.6  0.7  +  0.4  10  +  4  0-3  0  28-61 
* Number of cells  ￿  l03 scored in the growth assay. 
The growth assay was performed as described above, using optimal concentrations of the tested factors, as described in Materials and Methods. The production 
of PAF,  PCA,  and the expression of ELAM-1,  VCAM-1 and HLA-Dr antigen was measured in cells stimulated for 4 h (PCA),  6 h (PAF and ELAM-1), 
12 h (VCAM-1), and 96 h (HLA-Dr) with HGF (5 ng/ml), IL-I~ and TNFc~ (10 ng/ml), and INF3, (500 ng/ml) as described under Materials and Methods. A 
range of concentrations of HGF (from 0.1 to 100 ng/ml) and exposure times (from 5 min to 96 h) have been studied with results consistent with those selected 
for display in this table. Numbers are the mean (+ SD) calculated from triplicates of one representative experiment or ranges of three experiments done in duplicate. 
of accompanying  inflammatory  reaction  were  observed  as 
shown by the persistence of corneal transparency for all the 
duration of the experiment.  When  compared with the well- 
established  angiogenic  factor  bFGF,  HGF  showed  equal 
potency on  molar basis  (Table IV). 
Discussion 
The data reported here prove that HGF  is a powerful angio- 
genic  factor  stimulating  endothelial  cell  proliferation  and 
migration. 
Figure 9. Induction of angiogenesis in vivo by 
HGF.  A  vinyl copolymer pellet (P)  was  im- 
planted in the avascular cornea of rabbit eyes. 
The  upper  picture  shows  a  control  implant 
lacking HGE The lower picture shows a pellet 
containing 50 ng of HGF.  A network of newly 
formed blood vessels (arrow) sprouting from 
the limbus was observed. The neoformed ves- 
sels invaded the corneal stroma and reached the 
pellet releasing HGF.  Photographs were taken 
8  d  after the implant.  Bar,  1,000/~m. 
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Positive 
Factor  ng/pellet  implants  Potency 
HGF  0  0/8  - 
20  3/8  + 
50  6/8  + + + 
bFGF  0  0/10  - 
20  2/10  + + 
50  8/10  + + + 
Slow-releasing polyvinyl pellets containing different amounts of pure HGF or 
bFGF were implanted into the avascular cornea of rabbits. Angiogenic activity 
was expressed as the number of pellet implants inducing neovascularization of 
the peripheral stroma within 10 d. The potency of the angiogenic response was 
scored  on  the basis of the number of the  newly formed vessels observed 
without magnification. (-): no vessel growth; (+) vessel growth up to 0.6 mm 
from the limbus; (+ +) new vessel formation extending midway to the corneal 
pocket; (+ + +) new vessel formation reaching the corneal pocket,  p <  0.05 
for both factors (50 ng/peUet)  by Fischer's exact test. 
This effect is mediated by a  direct interaction with the 
specific receptor (pl90M~r), a  transmembrane tyrosine ki- 
nase encoded by the METoncogene (Park et al., 1986; Gon- 
zatti et al., 1988; Giordano et al., 1989a). Endothelial cells 
express the MET protooncogene and expose at the cell sur- 
face the mature protein  with the same c~-~ heterodimeric 
structure found in epithelial cells (Giordano et al.,  1989b; 
Di Renzo et al.,  1991; Prat et al., 1991). HGF binds to the 
endothelial cell surface through a high affinity site with a 
Kd comparable  to  that previously measured  in  epithelial 
cells (Naldini et al.,  1991a; Higuchi and Nakamura,  1991; 
Zarnegar et al.,  1991; Masumoto et al.,  1991). A distinct 
lower affinity, higher capacity binding site was also detected. 
The binding of HGF  to p190 MET at the endothelial cell 
surface is followed by the activation of the receptor tyrosine 
kinase domain and phosphorylation of the/3 subunit. Auto- 
phosphorylation of tyrosine kinase receptors  is known to 
trigger  intracellular  signals  leading  to  the  biological  re- 
sponses induced by the specific ligands (reviewed in Ullrich 
and Schlessinger,  1990).  Sub-nanomolar concentrations of 
HGF induce the proliferation of endothelial cells derived 
from human large vessels and from murine microvascular 
capillaries. This biological effect is highly specific and re- 
quires  the correct conformation of the ot and/3 chains of 
HGF, since a single amino acid substitution abolishes activ- 
ity. In this respect it is also intriguing that, in spite of the ho- 
mology between human and rodent HGF being higher than 
90% (Tashiro et al., 1990), cross-stimulations performed on 
human endothelial cells  with murine HGF and viceversa 
suggest some degree of species specificity.  A similar obser- 
vation has been reported studying the effect of HGF on hu- 
man and rat hepatocytes (Strain et al.,  1991). 
HGF markedly stimulates directed (chemotaxis) and ran- 
dom (chemokinesis) migration of endothelial cells. Prolifer- 
ation and motility are involved in the repair of mechanically 
wounded endothelial cells monolayers induced by HGE The 
wound healing is an in vitro model mimicking in vivo condi- 
tions where activation of cell motility is required (Heimark 
et al.,  1986).  In vitro wound healing induced by HGF was 
partially prevented  by mitomycin C,  an  inhibitor of cell 
proliferation. This shows that the repair mechanism induced 
by HGF is mediated by stimulation of both migration and 
growth of endothelial cells. 
A crucial step in the sequence of events that leads to the 
angiogenic response is the invasion of the perivascular ma- 
trix by sprouting endothelial cells. The process includes mo- 
tility and  proliferation  and  production  of lyric  enzymes 
enabling extracellular matrix penetration (reviewed in Folk- 
man and Klagsbrun,  1987; Ingberg  and Folkman,  1989; 
Sporn and Roberts,  1990). 
A model, known as "angiogenesis in vitro" (Montesano et 
al.,  1986),  mimics these steps  of the angiogenesis. Angio- 
genic factors,  like FGF and phorbol  esters  stimulate en- 
dothelial cells grown on collagene three-dimensional gels to 
invade and form capillary-like structure (Montesano et al., 
1986).  HGF  promotes  the  scattering  of endothelial cells 
monolayer within the underlying collagen matrix, suggesting 
that this factor is able to activate endothelial cells also in 
vitro conditions mimicking the in vivo microenvironment. 
Unlike other cytokines active on endothelial cells, such as 
IL-1/3, TNFct,  and IFN3~ (reviewed in Pober and Cotran, 
1990; Butcher,  1991; Osborn, 1990; Mantovani et al., 1992), 
HGF does not modulate functions related to hemostasis- 
thrombosis (synthesis of procoagulant activity and platelet 
activating factor), inflammation (expression of the cell adhe- 
sion molecules ELAM-1 and VCAM-1), or the so called ac- 
cessory functions (expression of HLA-Dr antigens). 
Having shown that HGF induces endothelial cell migra- 
tion and proliferation in several in vitro assays, it was impor- 
tant to investigate the in vivo relevance of these properties. 
HGF has a  clear angiogenic activity in the rabbit cornea, 
comparable to that promoted by bFGE In view of the effects 
induced in vitro, it is reasonable to assume that the angiogenic 
effect of HGF in vivo reflects a direct interaction with endo- 
thelial cells. However, we cannot exclude that the angiogenic 
activity of HGF involves other circuits mediated by epithelial 
cells activated by this cytokine. Thus, HGF is to be included 
in the group of factors that induce angiogenesis via modula- 
tion of endothelial cell locomotion and growth (reviewed in 
Folkman and Klagsbrun, 1987; Rifkin and Moscatelli, 1989; 
Sporn and Roberts,  1990). 
HGF is a potent mitogen and motogen for epithelial cells 
(reviewed in Gherardi and Stoker, 1991) and promotes their 
three-dimensional organization (Montesano et al.,  1991). 
We now show that HGF is also a potent angiogenic factor. 
The generation of new capillaries is a necessary event con- 
comitant to the assembly of  multicellular structures in physi- 
ological conditions and is implicated in several diseases, in- 
cluding development of solid tumors and metastases.  The 
multiple effects on epithelial cells matched to the angiogenic 
properties,  point  to  the  critical  role  of  HGF  in  these 
processes. 
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